Cardiac Gene-Silencing Therapies for Long-Term Modulation of Pathological Protein Expression

Abstract

Cardiac gene-silencing therapies represent an innovative approach to the long-term management of pathological protein expression implicated in various cardiovascular diseases. Leveraging technologies such as RNA interference (RNAi), antisense oligonucleotides (ASOs), and CRISPR-based genome editing, these interventions aim to specifically suppress or modulate the expression of deleterious proteins responsible for disease progression. This review explores the current state, clinical applications, and future prospects of gene-silencing strategies in cardiology, focusing on their mechanisms, clinical relevance, and integration into guideline-directed management of cardiac disorders.

Introduction

The advent of gene-silencing therapies has catalyzed a paradigm shift in the treatment of cardiovascular diseases characterized by aberrant protein expression. Traditional pharmacological interventions often target downstream effects rather than the molecular origins of disease. In contrast, gene-silencing strategies offer the potential for precise, durable modulation of pathogenic proteins, enabling disease modification at the genetic and transcriptomic levels. This review synthesizes the latest evidence on cardiac gene-silencing therapies, providing clinicians and researchers with an advanced understanding of their mechanisms, clinical applicability, and emerging role in cardiovascular medicine.

Epidemiology / Disease Burden

Cardiovascular diseases remain the leading cause of mortality worldwide, with an estimated 18 million deaths annually. Familial cardiomyopathies, hereditary amyloidosis, and certain arrhythmogenic conditions are often driven by the overexpression or aberrant production of specific proteins. For instance, transthyretin amyloidosis (ATTR), hypertrophic cardiomyopathy (HCM), and familial hypercholesterolemia (FH) each have well-characterized genetic bases that result in persistent pathological protein activity. Despite advances in conventional therapies, the long-term disease burden and recurrent hospitalizations underscore the need for innovative treatments targeting the root causes at the genetic level.

Pathophysiology

Many cardiac disorders result from the accumulation or aberrant function of proteins encoded by mutated or dysregulated genes. For example, mutant transthyretin (TTR) proteins aggregate and deposit in cardiac tissue in ATTR, while pathogenic variants in sarcomeric proteins drive maladaptive remodeling in HCM. These pathogenic proteins disrupt normal cellular processes, promoting apoptosis, fibrosis, and systolic or diastolic dysfunction. Gene-silencing therapies aim to attenuate the synthesis of these proteins, thereby mitigating the cascade of downstream pathological events and potentially reversing or preventing disease progression.

Risk Factors

Risk factors for diseases amenable to gene-silencing therapy include genetic predisposition, family history of inherited cardiac conditions, and specific pathogenic gene variants. Lifestyle factors, such as diet and exercise, may modulate disease expression but are insufficient to counteract the effects of highly penetrant mutations. Early identification of at-risk individuals through genetic screening and cascade testing is critical for timely intervention and the potential application of gene-silencing strategies.

Clinical Features

The clinical features of protein-driven cardiac diseases vary according to the underlying genetic abnormality. In ATTR, patients present with restrictive cardiomyopathy, heart failure, arrhythmias, and conduction disturbances. HCM is characterized by left ventricular hypertrophy, diastolic dysfunction, and increased risk of sudden cardiac death, while FH manifests as premature atherosclerosis and coronary artery disease. The phenotypic spectrum and disease severity depend on the degree of pathogenic protein expression, underscoring the rationale for targeted gene-silencing interventions.

Diagnosis

Definitive diagnosis of genetic cardiac diseases relies on a combination of clinical evaluation, imaging, biochemical markers, and molecular genetic testing. Echocardiography and cardiac MRI are essential for phenotypic characterization, while mass spectrometry and immunohistochemistry aid in identifying protein deposits in amyloidosis. Next-generation sequencing and targeted mutation analysis enable detection of causative gene variants, providing the basis for personalized gene-silencing therapy selection and monitoring.

Treatment & Management

Conventional management of protein-driven cardiac diseases includes pharmacotherapy, device implantation, and, in advanced cases, heart transplantation. However, these approaches often treat symptoms rather than the underlying cause. Gene-silencing therapies, delivered via intravenous or subcutaneous routes, directly target mRNA or DNA to suppress pathogenic protein production. Clinical use of ASOs (e.g., inotersen for ATTR) and siRNA (e.g., patisiran) has demonstrated efficacy in reducing cardiac amyloid burden, improving functional status, and prolonging survival. Multidisciplinary management and regular monitoring for adverse effects, such as thrombocytopenia and renal dysfunction, are critical for optimizing outcomes.

Recent Advances / Emerging Therapies

Recent breakthroughs include the approval of RNAi and ASO agents for ATTR cardiomyopathy, with ongoing trials evaluating their use in other genetic cardiomyopathies. CRISPR/Cas9-based genome editing has shown proof-of-concept success in preclinical models, offering the potential for permanent gene correction with a single intervention. Lipid nanoparticle delivery systems and tissue-specific promoters are being developed to enhance cardiac targeting and minimize off-target effects. Combination approaches, integrating gene-silencing with traditional therapies, are under investigation to optimize disease control and improve patient quality of life.

Guideline Recommendations

International guidelines now recognize gene-silencing therapies as viable options for selected patients with cardiac amyloidosis and other monogenic cardiac disorders. The American Heart Association and European Society of Cardiology recommend genetic counseling, early diagnosis, and consideration of ASO or RNAi agents in eligible patients. Ongoing clinical trials and registries are expected to further refine patient selection criteria, safety monitoring, and long-term management protocols.

Conclusion

Cardiac gene-silencing therapies offer a transformative approach to the management of inherited and acquired heart diseases characterized by pathological protein expression. With expanding clinical evidence and technological advancements, these therapies are poised to become integral components of precision cardiovascular medicine. Continued research, multidisciplinary collaboration, and real-world data will be essential to fully realize their potential and optimize outcomes for patients with protein-driven cardiac disorders.